神经在线 第2页
排序
Negative Myoclonus Associated With Severe Motor Implications in Progressive Myoclonus Ataxia
Marina A.J. Tijssen, MD, PhD(Credit: University of Groningen)In a newly published study in Movement Disorders, patients with progressive myoclonus ataxia (PMA) affected by negative...
12个月前
Crossover Study Highlights Pharmacokinetic Effects of DHE Powder STS101
A recently published, randomized, open-label, 5-period crossover study showed that treatment with STS101, an intranasal dihydroergotamine (DHE) powder, was safe in healthy particip...
12个月前
ALS Candidate PrimeC Shows Greater Treatment Effect in High-Risk ALS
Jeremy M. Shefner, MD, PhDNewly announced analyses from the phase 2b PARADIGM trial (NCT05357950) showed that treatment with PrimeC (NeuroSense), an investigational agent made up o...
12个月前
Criteria for Changing Treatment in Narcolepsy: Part 2
This is a video synopsis/summary of a panel discussion involving Michael Thorpy, MD; Karl Doghramji, MD, FAASM, DFAPA; Clete Kushida, MD, PhD; and Richard K Bogan, MD.The discussio...
12个月前
Closing Thoughts and Outlook of PD Care
At the 2024 American Academy of Neurology Annual Meeting, NeurologyLive® sat down with Parkinson disease (PD) expert Daniel Kremens, MD, JD, to discuss some of the top data being ...
12个月前Criteria for Changing Treatment in Narcolepsy: Part 1
This is a video synopsis/summary of a panel discussion involving Michael Thorpy, MD; Karl Doghramji, MD, FAASM, DFAPA; Clete Kushida, MD, PhD; and Richard K Bogan, MD.Experts discu...
12个月前
NeurologyLive® Brain Games: May 12, 2024
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topi...
12个月前
Patient Death Reported in Phase 2 DAYLIGHT Study of Pfizer’s Gene Therapy for Duchenne
A patient in the phase 2 DALIGHT trial (NCT05429372) assessing Pfizer’s investigational gene therapy fordadistrogene movaparvovec (PF-06939926) in boys with Duchenne muscular dyst...
12个月前Overlooked Neurological Features Present in Long COVID: Svetlana Blitshteyn, MD, FAAN
WATCH TIME: 3 minutes'For many years, those of us who specialize in these disorders have seen patients with very similar features that the patients with Long COVID have. Many of th...
12个月前PrimeC Performs Well in High-Risk ALS, Patient Death Reported in DAYLIGHT Trial, Donanemab AdComm Hearing Date Announced
WATCH TIME: 4 minutesWelcome to this special edition of Neurology News Network. I’m Marco Meglio.Newly announced analyses from the phase 2b PARADIGM trial showed that treatment wi...
12个月前
